We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.3%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.83B
AUM Growth
-$193M
Cap. Flow
-$2.01B
Cap. Flow %
-41.54%
Top 10 Hldgs %
42.39%
Holding
141
New
14
Increased
13
Reduced
19
Closed
37

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$95.6M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$71.9M
3
AMED
Amedisys
AMED
+$70M
4
PCVX icon
Vaxcyte
PCVX
+$27.5M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$24.7M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$94.9M
2
BIIB icon
Biogen
BIIB
+$88.1M
3
AERI
Aerie Pharmaceuticals
AERI
+$73.5M
4
LUNG icon
Pulmonx
LUNG
+$62M
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$55.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.42%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WINT
101
DELISTED
Windtree Therapeutics
WINT
– –
0
– -$6K
KNTE
102
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-250,000
Closed -$2.99M
PNT
103
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-1,000,000
Closed -$7.73M
ISEE
104
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,000,000
Closed -$17.9M
SNRH
105
DELISTED
Senior Connect Acquisition Corp. I Class A Common Stock
SNRH
– –
-1,000,000
Closed -$9.95M
EUCR
106
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
– –
-999,999
Closed -$10M
PKBO
107
DELISTED
Peak Bio, Inc. Common Stock
PKBO
– –
-725,000
Closed -$7.24M
REVH
108
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
– –
-1,000,000
Closed -$9.82M
REVHW
109
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Warrant.
REVHW
– –
-200,000
Closed -$9K
OHPA
110
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
– –
-500,000
Closed -$4.92M
OHPAW
111
DELISTED
Orion Acquisition Corp. Warrant
OHPAW
– –
-125,000
Closed -$7K
AERI
112
DELISTED
Aerie Pharmaceuticals
AERI
– –
-4,855,005
Closed -$73.5M
SRSAU
113
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
– –
-1
Closed –
SRSAW
114
DELISTED
Sarissa Capital Acquisition Corp. Warrants
SRSAW
– –
-333,333
Closed -$7K
SRSA
115
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
– –
-999,999
Closed -$10M
TMPMW
116
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
– –
-250,000
Closed -$7K
TMPM
117
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
– –
-750,000
Closed -$7.5M
1 2 3 4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2022 Portfolio in Review

As of Q4 2022, Deerfield Management held 141 positions worth $4.83B, down 3.8% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $2.01B in Q4 2022, closing 37 positions and reducing 19 holdings. Its most notable exit was Gilead Sciences, an estimated $94.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Amylyx Pharmaceuticals worth $99.5M.

  • Deerfield Management's largest Q4 2022 buy was Amylyx Pharmaceuticals: 2,693,000 shares worth $99.5M.
  • Deerfield Management added most to Amedisys in Q4 2022, an estimated $70M increase.
  • Deerfield Management's biggest Q4 2022 reduction was Silk Road Medical, Inc. Common Stock, cutting an estimated $55.5M.
  • Deerfield Management fully exited Gilead Sciences in Q4 2022, selling an estimated $94.9M.
  • Deerfield Management's ten largest holdings make up 42% of its $4.83B portfolio in Q4 2022.
  • Deerfield Management opened 14 new positions and closed 37 in Q4 2022.
  • Deerfield Management's portfolio value fell 3.8% quarter-over-quarter to $4.83B.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.